Brokerages Set KKR & Co. Inc. (NYSE:KKR) PT at $151.64

KKR & Co. Inc. (NYSE:KKR) has received a consensus recommendation of “Buy” from the sixteen research firms that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation, twelve have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $151.64.

Several analysts have recently commented on KKR shares. Barclays lifted their price target on shares of KKR & Co. Inc. from $149.00 to $166.00 and gave the company an “overweight” rating in a research report on Friday, October 25th. Morgan Stanley upped their price target on KKR & Co. Inc. from $107.00 to $143.00 and gave the company an “equal weight” rating in a research note on Thursday, October 10th. JMP Securities raised their price objective on KKR & Co. Inc. from $150.00 to $155.00 and gave the stock a “market outperform” rating in a research report on Tuesday, October 29th. Citigroup boosted their price objective on shares of KKR & Co. Inc. from $157.00 to $171.00 and gave the company a “buy” rating in a report on Friday, October 25th. Finally, Oppenheimer increased their target price on shares of KKR & Co. Inc. from $128.00 to $148.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 16th.

Insider Activity

In related news, major shareholder Genetic Disorder L.P. Kkr sold 5,800,000 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $25.75, for a total value of $149,350,000.00. Following the sale, the insider now owns 25,260,971 shares of the company’s stock, valued at $650,470,003.25. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other KKR & Co. Inc. news, major shareholder Genetic Disorder L.P. Kkr sold 5,800,000 shares of the firm’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $25.75, for a total value of $149,350,000.00. Following the sale, the insider now directly owns 25,260,971 shares in the company, valued at $650,470,003.25. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Kkr Group Partnership L.P. bought 11,619,998 shares of the business’s stock in a transaction dated Wednesday, September 11th. The shares were acquired at an average cost of $11.13 per share, for a total transaction of $129,330,577.74. Following the transaction, the insider now directly owns 92,959,984 shares in the company, valued at approximately $1,034,644,621.92. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 39.34% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. GQG Partners LLC acquired a new position in KKR & Co. Inc. in the first quarter valued at $217,004,000. Canada Pension Plan Investment Board boosted its position in shares of KKR & Co. Inc. by 198.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 3,207,368 shares of the asset manager’s stock valued at $337,543,000 after purchasing an additional 2,133,290 shares during the period. Bank of New York Mellon Corp boosted its position in shares of KKR & Co. Inc. by 64.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 4,036,821 shares of the asset manager’s stock valued at $424,835,000 after purchasing an additional 1,585,447 shares during the period. APG Asset Management N.V. purchased a new position in KKR & Co. Inc. during the 2nd quarter worth approximately $154,468,000. Finally, Capital World Investors increased its position in KKR & Co. Inc. by 7.4% during the first quarter. Capital World Investors now owns 16,644,897 shares of the asset manager’s stock worth $1,674,144,000 after buying an additional 1,139,784 shares during the period. Institutional investors and hedge funds own 76.26% of the company’s stock.

KKR & Co. Inc. Price Performance

KKR stock opened at $152.22 on Thursday. KKR & Co. Inc. has a 1 year low of $59.08 and a 1 year high of $153.51. The company has a debt-to-equity ratio of 0.86, a current ratio of 0.07 and a quick ratio of 0.07. The firm has a market capitalization of $135.09 billion, a PE ratio of 46.27, a price-to-earnings-growth ratio of 1.13 and a beta of 1.61. The business has a 50 day simple moving average of $131.67 and a 200-day simple moving average of $116.57.

KKR & Co. Inc. (NYSE:KKR) last announced its quarterly earnings results on Thursday, October 24th. The asset manager reported $1.38 earnings per share for the quarter, beating the consensus estimate of $1.03 by $0.35. The firm had revenue of $4.79 billion for the quarter, compared to analysts’ expectations of $1.23 billion. KKR & Co. Inc. had a net margin of 13.21% and a return on equity of 5.86%. During the same quarter in the previous year, the company posted $0.73 EPS. Equities research analysts anticipate that KKR & Co. Inc. will post 4.04 earnings per share for the current fiscal year.

KKR & Co. Inc. Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, November 19th. Shareholders of record on Monday, November 4th will be issued a dividend of $0.175 per share. The ex-dividend date is Monday, November 4th. This represents a $0.70 annualized dividend and a yield of 0.46%. KKR & Co. Inc.’s dividend payout ratio (DPR) is 21.28%.

About KKR & Co. Inc.

KKR & Co Inc is a private equity and real estate investment firm specializing in direct and fund of fund investments. It specializes in acquisitions, leveraged buyouts, management buyouts, credit special situations, growth equity, mature, mezzanine, distressed, turnaround, lower middle market and middle market investments.